Israeli wireless medical monitoring system installed in 15 hospitals

“Currently, the company has deployed advanced monitoring systems in all coronavirus isolation units at 15 medical centers in Israel."

Magen David Adom worker test kit as he arrives for a patient with symptoms of COVID-19 (coronavirus), in Jerusalem on March 17, 2020 (photo credit: YONATAN SINDEL/FLASH90)
Magen David Adom worker test kit as he arrives for a patient with symptoms of COVID-19 (coronavirus), in Jerusalem on March 17, 2020
(photo credit: YONATAN SINDEL/FLASH90)
A Petach Tikvah company has developed a first of its kind wireless medical monitoring system that enables monitoring of coronavirus patients without hospitalization, reducing contact between them and medical teams and preventing the risk of doctors and nurses being infected.
 
About 3,000 of their BioBeat systems have been installed recently in 15 Israeli medical centers.
The BioBeat system, a sticker affixed to the chest, continuously monitors 16 advanced physiologic metrics, and the medical information is transmitted in real time to the medical staff in the hospital.
Among the medical centers using the system are Ichilov, Tel Hashomer, Rambam and Shaare Zedek.
The BioBeat-developed LED-based sensor reads data such as: respiratory rate, blood oxygen percentage, pulse, continuous blood pressure, HRV, heart rate, heart output, body temperature, SVR and patient movement.
The data is transmitted via BT to a secure cloud that complies with medical information security standards and is broadcast to all types of media: cell phones, tablets, computers and TV screens.
This enables continuous, effective and accurate monitoring of patients, while reducing contact between them and the medical staff. Precisely for this reason, the system provides an advanced solution for isolation, as is necessary in the case of people infected with the coronavirus.
The company is the only one in the world to hold FDA approval, which was issued in August 2019, for continuous blood pressure measurement without the need for a pressure cuff.
In addition to monitoring itself, the system enables an advanced analysis of the physiological effect of the virus on humans, as well as assessing the effectiveness of medical care provided to patients.
BioBeat stands at the forefront of the response and supports medical teams.
To date, the company has raised $2.5 million with revenues of more than $10 million.
BioBeat is owned by three founders: CEO Arik Ben Ishay, VP of technology Johanan May and VP of research and development Israel Sarussi.


Tags hospital